Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AbbVie said on Thursday its therapy to treat patients with a type of ovarian cancer has met the main goal of a mid-stage trial.

AbbVie's ovarian cancer therapy succeeds in mid-stage trial

PICCOLO trial met its primary endpoint of objective response rate (ORR) Data from the study will be presented at a future medical meeting NORTH CHICAGO, Ill. , June 6, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today positive topline results from the Phase 2 PICCOLO trial evaluating investigational mirvetuximab soravtansine (ELAHERE®) monotherapy in heavily pre-treated patients with folate receptor-alpha (FRα) positive, platinum-sensitive ovarian cancer (PSOC).

AbbVie Announces Positive Topline Results from Phase 2 PICCOLO Trial Evaluating Mirvetuximab Soravtansine (ELAHERE®) for High Folate Receptor-Alpha (FRα) Expressing Platinum-Sensitive Ovarian Cancer

Allē Members Can Celebrate with Double Points and Enter for a Chance to Win $5,000 IRVINE, Calif. , June 6, 2024 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), the makers of BOTOX® Cosmetic (onabotulinumtoxinA), is celebrating 25 years of SkinMedica®.

SkinMedica® Celebrates 25 Years of Empowering Radiant Skin

The submission period is now open to individuals living with migraine for the new AbbVie Migraine Career Catalyst Award™ contest, awarding winners with a financial prize that they may decide to use to support their career and professional development goals As the only company with three treatment options designed to meet patient needs across the spectrum of migraine, AbbVie is dedicated to addressing the impact of migraine in the workplace NORTH CHICAGO, Ill. , June 6, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today launched the AbbVie Migraine Career Catalyst Award TM, a first-of-its-kind contest designed to support the career, workplace, and professional development aspirations of people living with migraine.

AbbVie Launches First-of-its-Kind Contest to Empower People Living with Migraine in their Careers

Alphabet

JPMorgan Chase & Co

Coca-Cola

Microsoft

UnitedHealth Group

Exxon Mobil

With the market entering a historically challenging season (due to the adage buy in May and go away), jittery investors may want to turn to stocks to buy tacitly endorsed by the hedge funds and other institutional players. Basically, if the big dogs like these ideas, you might want to consider adding some yourself.

Hedge Fund Favorites: 7 Stocks to Buy When You're Feeling Jittery

Moderna

Novo Nordisk

The biotech sector has been through a lot in the past five years and it is finally rebounding. One of the most important sectors globally, it is hard to imagine life without biotech companies that provide life-changing drugs.

Biotech Blockbusters: 3 Pharma Stocks to Buy in June for Breakthrough Potential

Pfizer

High-yield dividend stocks typically outperform the broader markets over long periods. AbbVie and Pfizer are two attractively priced high-yield dividend stocks worth considering right now.

2 High-Yield Dividend Stocks to Buy Right Now

ABBV-383 is a B-cell maturation antigen (BCMA) bispecific antibody T-cell engager being evaluated in relapsed/refractory multiple myeloma (r/r MM) The CERVINO Phase 3 trial will evaluate the efficacy, safety, and tolerability of ABBV-383 monotherapy compared with standard available therapies (SATs) in patients with r/r MM who have received at least two lines of prior therapy NORTH CHICAGO, Ill. , June 5, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the first patient has been treated with investigational ABBV-383 in the CERVINO Phase 3 study.

AbbVie Advances Oncology Pipeline With Start of Multiple Myeloma Phase 3 Clinical Trial for Investigational Asset ABBV-383

Sysco

Walmart

The timing is perfect for loading up on dividend stocks as market experts expect the S&P 500 to increase 4% in June following a 5% rise in May as three potential rate cuts loom, possibly boosting already solid corporate profitability. Meanwhile, 97% of S&P 500 companies reported first-quarter results that were 3% better than consensus.

The Dividend Dominators: 3 Stocks That Will Make Your Portfolio Reign Supreme

–   First indications of RINVOQ (upadacitinib) for pediatric patients two years of age and older1 –   RINVOQ is now approved for eight indications across immune-mediated inflammatory diseases 1 NORTH CHICAGO, Ill. , June 4, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that RINVOQ® (upadacitinib) is indicated in the U.S. for the treatment of pediatric patients two years of age and older with active polyarticular juvenile idiopathic arthritis (pJIA) as well as psoriatic arthritis (PsA), provided they have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers.

RINVOQ® (upadacitinib) Now Available for Pediatric Patients Two Years and Older with Polyarticular Juvenile Idiopathic Arthritis and Psoriatic Arthritis

Join Allē Today to Start Sharing and Earning Rewards Refer a Friend by Allē Lets Consumers Earn up to $50 to Use Towards Allergan Aesthetics Products and Treatments IRVINE, Calif. , June 4, 2024 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the debut of Refer a Friend, a new offering from Allē, the Allergan Aesthetics Loyalty Rewards Program.

Refer Your Friends to Allē, the Loyalty Rewards Program by Allergan Aesthetics, and Earn $50

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes?

AbbVie (ABBV) Could Be a Great Choice

AbbVie (ABBV) announces that the EMA's CHMP issued a positive opinion on its regulatory filing seeking label expansion for the immunology drug, Skyrizi, to treat UC.

AbbVie (ABBV) Skyrizi Gets CHMP Nod for Ulcerative Colitis in EU

NORTH CHICAGO, Ill. , June 3, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 2024.

AbbVie to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

Enphase Energy

Johnson & Johnson

Norwegian Cruise Line

PepsiCo

SoFi Technologies

The financial media does its best to keep you informed about what's happening in the market. However, this has the effect of giving significant attention to a handful of leaders or laggards.

7 Overlooked Stocks That Belong in Every Portfolio

AbbVie (ABBV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

AbbVie (ABBV) Soars 3.2%: Is Further Upside Left in the Stock?

AstraZeneca

Vertex Pharmaceuticals

AbbVie covers all the bases for investors -- income, value, and growth. AstraZeneca is an inexpensive stock that has solid growth opportunities.

3 No-Brainer Stocks to Buy in June

The positive opinion is based on results from two pivotal Phase 3 trials, INSPIRE and COMMAND, that evaluated the efficacy and safety of risankizumab in adults with moderately to severely active ulcerative colitis (UC)1,2 In both trials, the primary endpoint of clinical remission (per Adapted Mayo Score*) and key secondary endpoints, including endoscopic improvement** and histologic-endoscopic mucosal improvement,† were met1,2 UC is a chronic, idiopathic, immune-mediated inflammatory bowel disease (IBD) affecting the large intestine. It can lead to a substantial burden and often results in disability3-6 NORTH CHICAGO, Ill.

AbbVie Receives Positive CHMP Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis

AbbVie stock has fallen into a correction, declining nearly 16% from its March 2024 highs. Despite the pullback, AbbVie remains a highly profitable company with a strong portfolio and robust long-term guidance. The stock valuation is not cheap, but ABBV's 4% dividend yield may provide valuation support.

AbbVie: Turnaround Lurking After The Correction Pain (Upgrade)

AbbVie, a key player in my dividend growth portfolio, boasts a strong 4% yield and a consistent record of annual hikes. Its robust product lineup and innovative pipeline promise growth. Despite losing Humira's patent, AbbVie's new drugs, Skyrizi and Rinvoq, drive impressive revenue growth. The company continues to outperform the market with a solid return profile. Trading at a reasonable P/E ratio, AbbVie combines growth potential and reliable income.

Looking For Both Income And Growth? 4%-Yielding AbbVie Has You Covered

New safety and efficacy data in heavily pre-treated patients with metastatic colorectal cancer (CRC), from a Phase 1 study of ABBV-400, a next-generation, potential best-in-class c-Met directed ADC. Data from a first-in-human study of ABBV-706, a potential best-in-class SEZ6 directed ADC, in small cell lung cancer (SCLC), high-grade central nervous system (CNS) tumors and high-grade neuroendocrine neoplasms (NENs).

AbbVie Showcases Robust Solid Tumor Pipeline at ASCO 2024 with New Data from Its Innovative Antibody-Drug Conjugate (ADC) Platform

Arcellx

Agenus

BridgeBio Pharma Inc

Coya Therapeutics Inc

CRISPR Therapeutics

For those seeking to decipher best speculative opportunities in the market, biotech stocks with breakthrough potential may offer plenty of firepower. Let's get some of the bad stuff out of the way first.

7 Biotech Stocks to Put on Your Breakthrough Radar

Nvidia's high valuation could make the stock vulnerable to a sell-off if the company fall short of expectations. AbbVie is a top healthcare company with underrated growth prospects.

Forget Nvidia, Buy This Magnificent Healthcare Stock Instead

Lamb Weston Hlds

JPMorgan CEO Jamie Dimon expressed concern about inflation and predicts higher interest rates for longer than expected. He highlighted secular drivers such as the energy transition, geopolitical issues, infrastructure spending, and large deficits/debt levels. The favorable period for inflation in developed nations from 2009 to 2021 is likely over.

High Yields And Low Multiples - 3 Of My Favorite Dividend Stocks To Buy Right Now

Landos Biopharma

-   Adds first-in-class investigational asset, NX-13, to AbbVie's pipeline with the potential to offer a novel approach to the treatment of ulcerative colitis (UC) and Crohn's disease (CD) NORTH CHICAGO, Ill. , May 23, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Landos Biopharma, Inc. (NASDAQ: LABP).

News for AbbVie Stock (ABBV)